课题基金 / 基金详情

Program to enrich translation and multimodal research in Alzheimers disease and related dementias

Program to enrich translation and multimodal research in Alzheimers disease and related dementias
丰富阿尔茨海默病和相关痴呆症翻译和多模式研究的计划
批准号:
10090239
负责人:
Julie C Price
金额:
$41.66万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-03-01 至 2026-02-28

项目摘要

项目成果

Julie C Price的其他基金

相关文献

中文摘要
翻译
摘要 这是一份T32培训拨款申请的重新提交,该申请的标题是“丰富翻译和 阿尔茨海默病和相关痴呆症的多模式研究(PET和MR in ADRD)“。主要目标是 提供丰富的两年多模式神经成像博士后培训经验,重点是:[1] 衰老和神经退化生物学;[2]数据科学、计算生物学、统计学、数学、 工程学、生物物理学;以及[3]药物发现和药物开发学科。 这个T32项目背后的理由是多方面的。首先,必须为学员提供 利用现有技术的优势、推进新兴技术开发的工具,以及 确定推进阿尔茨海默病(AD)治疗开发的创新路径。这件事的意义 过去的许多AD试验失败,以及最近的几次试验提供了新的希望,这突显了培训。 其次,神经成像扩大了我们对生活中与年龄和疾病相关的大脑变化的了解 人类,并被证明是发现和开发新药的有用工具。神经成像 在试验研究设计和药物中期评估中,措施通常被视为合格标准。 性能。第三,AD和AD相关痴呆的PET和MRI确保了多学科团队的培训 科学。 这个T32将支持4个博士后培训名额,由博士、医学博士和/或医学博士/博士申请者填补。 将有20名高级教员和7名初级教员,主要隶属于MGH Martinos Center for 生物医学成像和马萨诸塞州阿尔茨海默病研究中心。两家公司的董事 中心是T32名教职员工。这些中心强烈支持多样性和包容性。我们的目标是招募女性 和代表不足的少数族裔(URM)进入4个插槽中的3个,以帮助满足对多样化劳动力的需求 以及URM对AD相关研究的参与。培训包括负责任地进行研究和 职业道德和职业发展。 每名学员将配备一名初级导师、一名二级导师和一名初级教师导师。这 将有助于确保在主要和次要重点领域提供强有力的指导,并促进团队建设和 反馈。所有学员将在暑期培训计划中担任导师。对T32计划的评估将 包括年度外部咨询委员会会议审查(哈佛医学院以外的所有成员 (学校)、一年两次的内部指导委员会会议和季度实习生评价。实习生将 在严谨的研究实践、不同的团队科学和指导方面获得经验,并将很好地 准备在T32训练期结束时在AD相关研究中寻求独立资金。
英文摘要
Abstract This is the resubmission of a T32 training grant application entitled “Program to enrich translation and multimodal research in Alzheimer’s disease and related dementias (PET&MR in ADRD)”. The main goal is to provide a rich 2-year postdoctoral training experience in multimodal neuroimaging that focuses on: [1] the biology of aging and neurodegeneration; [2] data sciences, computational biology, statistics, mathematics, engineering, biophysics; and [3] drug discovery and drug development disciplines. The rationale behind this T32 program is multi-faceted. First, it is essential to provide trainees with the tools to leverage strengths of existing technologies, advance development of emerging technologies, and identify innovative paths for advancing Alzheimer’s disease (AD) therapy development. The significance of this training is underscored by many past AD trial failures and renewed promise offered by a few recent trials. Second, neuroimaging has expanded our knowledge of age- and disease-related brain changes in living humans and proven to be a useful tool in the discovery and development of new drugs. Neuroimaging measures are often considered as eligibility criteria in trial study designs and for interim assessment of drug performance. Third, PET and MRI in AD and AD-related dementias ensures training in multidisciplinary team science. This T32 will support 4 postdoctoral training slots to be filled by PhD, MD, and/or MD/PhD applicants. There will be 20 senior faculty and 7 junior faculty, largely affiliated with the MGH Martinos Center for Biomedical Imaging and the Massachusetts Alzheimer’s Disease Research Center. The Directors of both centers are T32 faculty. These centers strongly support diversity and inclusion. Our goal is to recruit women and underrepresented minorities (URM) into 3 of the 4 slots to help address the need for a diverse workforce and URM participation in AD-related research. Training includes the responsible conduct of research and ethics and career development. Each trainee will be matched with a primary mentor, secondary mentor, and a junior faculty mentor. This will help to ensure strong mentorship in primary and secondary focus areas and facilitate team building and feedback. All trainees will serve as mentors in summer training programs. Evaluation of the T32 program will include an annual External Advisory Committee meeting review (all members external to Harvard Medical School), biannual Internal Steering Committee meetings; and quarterly trainee evaluations. The trainees will gain experience in rigorous research practices, diverse team science, and mentoring and will be well positioned to pursue independent funding in AD-related research at the end of the T32 training period.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Program to enrich translation and multimodal research in Alzheimers disease and related dementias
  • 批准号:
    10590747
  • 项目类别:
  • 资助金额:
    $37.35万
  • 财政年份:
    2021
  • 负责人:
    Julie C Price
  • 依托单位:
Program to enrich translation and multimodal research in Alzheimers disease and related dementias
  • 批准号:
    10347287
  • 项目类别:
  • 资助金额:
    $36.41万
  • 财政年份:
    2021
  • 负责人:
    Julie C Price
  • 依托单位:
Translation of tau-selective PET radiopharmaceuticals in Alzheimers patients
  • 批准号:
    10177826
  • 项目类别:
  • 资助金额:
    $47.97万
  • 财政年份:
    2018
  • 负责人:
    Julie C Price
  • 依托单位:
Translation of tau-selective PET radiopharmaceuticals in Alzheimers patients
  • 批准号:
    9763398
  • 项目类别:
  • 资助金额:
    $76.56万
  • 财政年份:
    2018
  • 负责人:
    Julie C Price
  • 依托单位: